禾元生物：公司产品奥福民®已于2025年7月获批后按计划上市销售，医院准入、渠道铺货等工作正稳步推进

Core Viewpoint - The company, He Yuan Bio (688765.SH), is actively expanding its hospital coverage for its product, Aofumin®, which is set to be launched in July 2025, and is currently progressing with hospital access and distribution channels [1]. Group 1 - The company confirmed that its production and operations are normal, with no undisclosed major issues or operational difficulties [1]. - The company is addressing investor inquiries regarding the application of its albumin product in hospitals in Wuhan and is committed to providing updates through public information [1].